Independent audits and continuous monitoring of logistics providers — creating transparent GDP oversight for pharmaceutical companies and structured compliance documentation for logistics providers.
Must ensure that their transport providers comply with GDP requirements — but often lack structured, continuous oversight mechanisms.
Must demonstrate GDP compliance to pharmaceutical customers — but face repeated, overlapping audits from multiple clients.
An independent governance structure that creates a transparent compliance record for transport providers and structured oversight for pharmaceutical companies — replacing fragmented processes with a single, shared governance layer.
The governance model consists of four core elements that create continuous oversight of pharmaceutical transport providers.
Independent GDP transport audits conducted at logistics providers.
Structured evaluation and qualification status of the transport provider.
Ongoing monitoring of compliance performance and operational indicators.
Tracking and verification of corrective and preventive actions.
The framework produces structured governance reports that document compliance status and create transparency between pharmaceutical companies and logistics providers.
A structured overview of the governance status of a logistics provider. Supports pharmaceutical companies during internal reviews and regulatory inspections.
Enables logistics providers to demonstrate GDP compliance to existing or potential pharmaceutical customers.
The framework enables QA teams to demonstrate structured GDP oversight of transport providers.
Logistics companies can demonstrate transparent GDP compliance to their pharmaceutical clients.
If you work in pharmaceutical quality, supply chain or pharmaceutical logistics and would like to exchange views on GDP transport governance, we would be happy to connect.
Book a Conversation